Bio-Techne Corporation (TECH)
USD 50.49
(1.73%)
USD 50.49
(1.73%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 | 744.34 Million USD | -5.53% |
| 2023 | 672.17 Million USD | 13.2% |
| 2022 | 593.79 Million USD | -14.16% |
| 2021 | 691.72 Million USD | 7.01% |
| 2020 | 646.39 Million USD | -10.08% |
| 2019 | 718.82 Million USD | 39.83% |
| 2018 | 514.05 Million USD | -15.15% |
| 2017 | 605.82 Million USD | 142.11% |
| 2016 | 250.22 Million USD | 15.62% |
| 2015 | 216.42 Million USD | 221.94% |
| 2014 | 67.22 Million USD | 65.76% |
| 2013 | 40.55 Million USD | -9.64% |
| 2012 | 44.88 Million USD | 42.27% |
| 2011 | 31.54 Million USD | 85.31% |
| 2010 | 17.02 Million USD | 9.67% |
| 2009 | 15.52 Million USD | -23.3% |
| 2008 | 20.23 Million USD | 17.72% |
| 2007 | 17.19 Million USD | -43.0% |
| 2006 | 30.16 Million USD | 10.11% |
| 2005 | 27.39 Million USD | -2.29% |
| 2004 | 28.03 Million USD | 5.16% |
| 2003 | 26.65 Million USD | -15.98% |
| 2002 | 31.73 Million USD | -16.2% |
| 2001 | 37.86 Million USD | -3.56% |
| 2000 | 39.26 Million USD | 45.42% |
| 1999 | 27 Million USD | 196.7% |
| 1998 | 9.1 Million USD | 56.9% |
| 1997 | 5.8 Million USD | 5.45% |
| 1996 | 5.5 Million USD | 19.57% |
| 1995 | 4.6 Million USD | 21.05% |
| 1994 | 3.8 Million USD | 46.15% |
| 1993 | 2.6 Million USD | -42.22% |
| 1992 | 4.5 Million USD | 36.36% |
| 1991 | 3.3 Million USD | -2.94% |
| 1990 | 3.4 Million USD | 13.33% |
| 1989 | 3 Million USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q4 | 744.34 Million USD | 5.31% |
| 2024 FY | 744.34 Million USD | 10.74% |
| 2024 Q2 | 767.19 Million USD | 1.26% |
| 2024 Q1 | 757.61 Million USD | 12.71% |
| 2024 Q3 | 706.79 Million USD | -7.87% |
| 2023 Q4 | 672.17 Million USD | -5.33% |
| 2023 FY | 672.17 Million USD | 13.2% |
| 2023 Q2 | 536.29 Million USD | -10.55% |
| 2023 Q3 | 710.01 Million USD | 32.39% |
| 2023 Q1 | 599.56 Million USD | 0.97% |
| 2022 Q2 | 602.31 Million USD | -3.36% |
| 2022 Q1 | 623.23 Million USD | -9.9% |
| 2022 FY | 593.79 Million USD | -14.16% |
| 2022 Q4 | 593.79 Million USD | 1.23% |
| 2022 Q3 | 586.57 Million USD | -2.61% |
| 2021 Q4 | 691.72 Million USD | 28.88% |
| 2021 Q1 | 613.81 Million USD | -5.04% |
| 2021 FY | 691.72 Million USD | 7.01% |
| 2021 Q2 | 537.01 Million USD | -12.51% |
| 2021 Q3 | 536.7 Million USD | -0.06% |
| 2020 Q4 | 646.39 Million USD | -8.67% |
| 2020 FY | 646.39 Million USD | -10.08% |
| 2020 Q2 | 675.06 Million USD | -10.09% |
| 2020 Q1 | 750.8 Million USD | 4.45% |
| 2020 Q3 | 707.75 Million USD | 4.84% |
| 2019 FY | 718.82 Million USD | 39.83% |
| 2019 Q2 | 748.4 Million USD | -1.88% |
| 2019 Q3 | 726.35 Million USD | -2.95% |
| 2019 Q1 | 762.72 Million USD | 48.37% |
| 2019 Q4 | 718.82 Million USD | -1.04% |
| 2018 Q2 | 557.6 Million USD | -1.76% |
| 2018 Q4 | 514.05 Million USD | -8.18% |
| 2018 Q1 | 567.57 Million USD | -6.31% |
| 2018 FY | 514.05 Million USD | -15.15% |
| 2018 Q3 | 559.85 Million USD | 0.4% |
| 2017 Q1 | 622.08 Million USD | 148.61% |
| 2017 Q2 | 629.45 Million USD | 1.18% |
| 2017 Q3 | 625.5 Million USD | -0.63% |
| 2017 Q4 | 605.82 Million USD | -3.15% |
| 2017 FY | 605.82 Million USD | 142.11% |
| 2016 Q4 | 250.22 Million USD | -14.62% |
| 2016 Q3 | 293.08 Million USD | 5.77% |
| 2016 Q2 | 277.11 Million USD | -4.57% |
| 2016 Q1 | 290.37 Million USD | 34.17% |
| 2016 FY | 250.22 Million USD | 15.62% |
| 2015 Q2 | 298.31 Million USD | 32.68% |
| 2015 FY | 216.42 Million USD | 221.94% |
| 2015 Q1 | 224.84 Million USD | 234.46% |
| 2015 Q3 | 284.23 Million USD | -4.72% |
| 2015 Q4 | 216.42 Million USD | -23.86% |
| 2014 Q4 | 67.22 Million USD | 25.6% |
| 2014 FY | 67.22 Million USD | 65.76% |
| 2014 Q1 | 52.52 Million USD | 29.51% |
| 2014 Q2 | 53.63 Million USD | 2.11% |
| 2014 Q3 | 53.52 Million USD | -0.21% |
| 2013 Q3 | 40.78 Million USD | 35.91% |
| 2013 Q2 | 30 Million USD | -6.3% |
| 2013 Q1 | 32.02 Million USD | -28.65% |
| 2013 FY | 40.55 Million USD | -9.64% |
| 2013 Q4 | 40.55 Million USD | -0.55% |
| 2012 Q4 | 44.88 Million USD | 13.52% |
| 2012 Q3 | 39.53 Million USD | 47.85% |
| 2012 Q2 | 26.74 Million USD | -31.57% |
| 2012 FY | 44.88 Million USD | 42.27% |
| 2012 Q1 | 39.08 Million USD | 23.88% |
| 2011 Q4 | 31.54 Million USD | 90.71% |
| 2011 Q1 | 16.05 Million USD | -5.67% |
| 2011 Q2 | 13.67 Million USD | -14.86% |
| 2011 Q3 | 16.54 Million USD | 20.99% |
| 2011 FY | 31.54 Million USD | 85.31% |
| 2010 Q4 | 17.02 Million USD | -13.79% |
| 2010 FY | 17.02 Million USD | 9.67% |
| 2010 Q3 | 19.74 Million USD | 44.28% |
| 2010 Q2 | 13.68 Million USD | -14.67% |
| 2010 Q1 | 16.04 Million USD | 3.33% |
| 2009 Q1 | 19.25 Million USD | -4.85% |
| 2009 Q4 | 15.52 Million USD | 4.08% |
| 2009 FY | 15.52 Million USD | -23.3% |
| 2009 Q3 | 14.91 Million USD | 14.41% |
| 2009 Q2 | 13.03 Million USD | -32.31% |
| 2008 Q2 | 19.85 Million USD | 34.18% |
| 2008 Q3 | 20.16 Million USD | 1.53% |
| 2008 FY | 20.23 Million USD | 17.72% |
| 2008 Q1 | 14.8 Million USD | -13.92% |
| 2008 Q4 | 20.23 Million USD | 0.38% |
| 2007 Q1 | 27.5 Million USD | -8.81% |
| 2007 Q2 | 12.16 Million USD | -55.79% |
| 2007 FY | 17.19 Million USD | -43.0% |
| 2007 Q3 | 15.71 Million USD | 29.19% |
| 2007 Q4 | 17.19 Million USD | 9.44% |
| 2006 Q2 | 26.61 Million USD | 3.12% |
| 2006 Q3 | 25.75 Million USD | -3.23% |
| 2006 Q4 | 30.16 Million USD | 17.13% |
| 2006 FY | 30.16 Million USD | 10.11% |
| 2006 Q1 | 25.8 Million USD | -5.79% |
| 2005 Q1 | 29.67 Million USD | 5.86% |
| 2005 FY | 27.39 Million USD | -2.29% |
| 2005 Q3 | 31.74 Million USD | 16.82% |
| 2005 Q2 | 27.17 Million USD | -8.44% |
| 2005 Q4 | 27.39 Million USD | -13.7% |
| 2004 FY | 28.03 Million USD | 5.16% |
| 2004 Q3 | 29.2 Million USD | 5.07% |
| 2004 Q2 | 27.79 Million USD | 6.34% |
| 2004 Q1 | 26.13 Million USD | -1.97% |
| 2004 Q4 | 28.03 Million USD | -3.99% |
| 2003 Q1 | 36.52 Million USD | 15.11% |
| 2003 FY | 26.65 Million USD | -15.98% |
| 2003 Q4 | 26.65 Million USD | -9.9% |
| 2003 Q3 | 29.58 Million USD | 5.26% |
| 2003 Q2 | 28.1 Million USD | -23.04% |
| 2002 Q2 | 33.38 Million USD | -10.49% |
| 2002 FY | 31.73 Million USD | -16.2% |
| 2002 Q4 | 31.73 Million USD | -3.96% |
| 2002 Q3 | 33.03 Million USD | -1.03% |
| 2002 Q1 | 37.29 Million USD | -1.5% |
| 2001 Q4 | 37.86 Million USD | 2.49% |
| 2001 Q3 | 36.94 Million USD | -5.38% |
| 2001 Q1 | 37.41 Million USD | -4.72% |
| 2001 Q2 | 39.04 Million USD | 4.36% |
| 2001 FY | 37.86 Million USD | -3.56% |
| 2000 Q3 | 40.56 Million USD | -6.75% |
| 2000 Q1 | 46.6 Million USD | 72.59% |
| 2000 FY | 39.26 Million USD | 45.42% |
| 2000 Q4 | 39.26 Million USD | -3.21% |
| 2000 Q2 | 43.5 Million USD | -6.65% |
| 1999 Q3 | 26.8 Million USD | -3.6% |
| 1999 Q4 | 27 Million USD | 0.75% |
| 1999 Q2 | 27.8 Million USD | -7.64% |
| 1999 Q1 | 30.1 Million USD | 230.77% |
| 1999 FY | 27 Million USD | 196.7% |
| 1998 Q4 | 9.1 Million USD | 12.35% |
| 1998 Q3 | 8.1 Million USD | 17.39% |
| 1998 Q2 | 6.9 Million USD | -10.39% |
| 1998 FY | 9.1 Million USD | 56.9% |
| 1998 Q1 | 7.7 Million USD | 32.76% |
| 1997 Q2 | 5.7 Million USD | 3.64% |
| 1997 FY | 5.8 Million USD | 5.45% |
| 1997 Q4 | 5.8 Million USD | 18.37% |
| 1997 Q1 | 5.5 Million USD | 0.0% |
| 1997 Q3 | 4.9 Million USD | -14.04% |
| 1996 Q4 | 5.5 Million USD | 12.24% |
| 1996 FY | 5.5 Million USD | 19.57% |
| 1996 Q3 | 4.9 Million USD | 13.95% |
| 1996 Q2 | 4.3 Million USD | -15.69% |
| 1996 Q1 | 5.1 Million USD | 10.87% |
| 1995 Q1 | 3.9 Million USD | 2.63% |
| 1995 FY | 4.6 Million USD | 21.05% |
| 1995 Q4 | 4.6 Million USD | 17.95% |
| 1995 Q3 | 3.9 Million USD | 21.88% |
| 1995 Q2 | 3.2 Million USD | -17.95% |
| 1994 Q4 | 3.8 Million USD | -9.52% |
| 1994 Q1 | 3.8 Million USD | 46.15% |
| 1994 Q2 | 3.3 Million USD | -13.16% |
| 1994 Q3 | 4.2 Million USD | 27.27% |
| 1994 FY | 3.8 Million USD | 46.15% |
| 1993 FY | 2.6 Million USD | -42.22% |
| 1993 Q2 | 2 Million USD | -55.56% |
| 1993 Q3 | 2.5 Million USD | 25.0% |
| 1993 Q4 | 2.6 Million USD | 4.0% |
| 1993 Q1 | 4.5 Million USD | 0.0% |
| 1992 Q4 | 4.5 Million USD | 0.0% |
| 1992 FY | 4.5 Million USD | 36.36% |
| 1992 Q1 | 5.7 Million USD | 72.73% |
| 1992 Q2 | 4.2 Million USD | -26.32% |
| 1992 Q3 | 4.5 Million USD | 7.14% |
| 1991 Q4 | 3.3 Million USD | -5.71% |
| 1991 Q3 | 3.5 Million USD | -2.78% |
| 1991 Q2 | 3.6 Million USD | 0.0% |
| 1991 Q1 | 3.6 Million USD | 5.88% |
| 1991 FY | 3.3 Million USD | -2.94% |
| 1990 FY | 3.4 Million USD | 13.33% |
| 1990 Q4 | 3.4 Million USD | -2.86% |
| 1990 Q3 | 3.5 Million USD | -2.78% |
| 1990 Q2 | 3.6 Million USD | 12.5% |
| 1990 Q1 | 3.2 Million USD | 0.0% |
| 1989 FY | 3 Million USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Absci Corporation | 58.3 Million USD | -1176.653% |
| Adaptive Biotechnologies Corporation | 352.85 Million USD | -110.947% |
| Alnylam Pharmaceuticals, Inc. | 4.05 Billion USD | 81.624% |
| Alzamend Neuro, Inc. | 3.22 Million USD | -22974.779% |
| Apollomics, Inc. | 14.15 Million USD | -5159.238% |
| 180 Life Sciences Corp. | 5.38 Million USD | -13716.802% |
| Atossa Therapeutics, Inc. | 5.23 Million USD | -14115.814% |
| Bicycle Therapeutics plc | 224.41 Million USD | -231.685% |
| Barinthus Biotherapeutics plc | 27.51 Million USD | -2605.609% |
| BioXcel Therapeutics, Inc. | 130.21 Million USD | -471.646% |
| CASI Pharmaceuticals, Inc. | 51.1 Million USD | -1356.549% |
| Chimerix, Inc. | 19.74 Million USD | -3669.764% |
| CRISPR Therapeutics AG | 346.76 Million USD | -114.651% |
| Contineum Therapeutics, Inc. Class A Common Stock | 198.32 Million USD | -275.319% |
| EyePoint Pharmaceuticals, Inc. | 88.86 Million USD | -737.645% |
| Fortress Biotech, Inc. | 165.93 Million USD | -348.562% |
| Fortress Biotech, Inc. | 165.93 Million USD | -348.562% |
| Gritstone bio, Inc. | 125.91 Million USD | -491.126% |
| Allakos Inc. | 74.79 Million USD | -895.2% |
| Boundless Bio, Inc. Common Stock | 256.97 Million USD | -189.654% |
| Cara Therapeutics, Inc. | 68.75 Million USD | -982.535% |
| Cytokinetics, Incorporated | 1.21 Billion USD | 38.517% |
| enGene Holdings Inc. Common Stock | 14.47 Million USD | -5042.956% |
| Innoviva, Inc. | 568.55 Million USD | -30.919% |
| Hoth Therapeutics, Inc. | 704.98 Thousand USD | -105482.688% |
| NLS Pharmaceutics AG | 10.68 Million USD | -6869.343% |
| RAPT Therapeutics, Inc. | 26.29 Million USD | -2730.836% |
| Salarius Pharmaceuticals, Inc. | 1.29 Million USD | -57190.372% |
| Terns Pharmaceuticals, Inc. | 13.15 Million USD | -5560.38% |
| Vigil Neuroscience, Inc. | 24.6 Million USD | -2925.035% |
| ImmuCell Corporation | 18.81 Million USD | -3856.094% |
| IDEAYA Biosciences, Inc. | 28.22 Million USD | -2537.072% |
| Incyte Corporation | 1.59 Billion USD | 53.253% |
| Inovio Pharmaceuticals, Inc. | 55.59 Million USD | -1238.854% |
| Lexaria Bioscience Corp. | 403.9 Thousand USD | -184184.54% |
| Mustang Bio, Inc. | 17.61 Million USD | -4124.644% |
| MiMedx Group, Inc. | 96.33 Million USD | -672.698% |
| MEI Pharma, Inc. | 8.35 Million USD | -8808.917% |
| MacroGenics, Inc. | 154.2 Million USD | -382.689% |
| Monopar Therapeutics Inc. | 1.75 Million USD | -42254.783% |
| Mereo BioPharma Group plc | 15.96 Million USD | -4563.2% |
| Marker Therapeutics, Inc. | 3.07 Million USD | -24107.375% |
| Marinus Pharmaceuticals, Inc. | 154.14 Million USD | -382.889% |
| Maravai LifeSciences Holdings, Inc. | 697.56 Million USD | -6.705% |
| Minerva Neurosciences, Inc. | 85.35 Million USD | -772.02% |
| NeuroBo Pharmaceuticals, Inc. | 6.09 Million USD | -12110.302% |
| NeuroSense Therapeutics Ltd. | 5.05 Million USD | -14639.406% |
| NextCure, Inc. | 14.99 Million USD | -4863.259% |
| Orchestra BioMed Holdings, Inc. | 27.16 Million USD | -2639.667% |
| Ocuphire Pharma, Inc. | 4.04 Million USD | -18315.141% |
| Onconetix, Inc. | 23.18 Million USD | -3111.007% |
| Oncternal Therapeutics, Inc. | 6.67 Million USD | -11047.821% |
| Opthea Limited | 264.6 Million USD | -181.306% |
| Ovid Therapeutics Inc. | 56.22 Million USD | -1223.744% |
| Psyence Biomedical Ltd. | 12.1 Million USD | -6049.182% |
| PDS Biotechnology Corporation | 33.25 Million USD | -2138.002% |
| Precigen, Inc. | 41.64 Million USD | -1687.388% |
| Pieris Pharmaceuticals, Inc. | 11.92 Million USD | -6143.416% |
| Prime Medicine, Inc. | 60.78 Million USD | -1124.646% |
| PureTech Health plc | 125.58 Million USD | -492.708% |
| Rocket Pharmaceuticals, Inc. | 73.76 Million USD | -909.042% |
| Regeneron Pharmaceuticals, Inc. | 7.1 Billion USD | 89.527% |
| Replimune Group, Inc. | 113.21 Million USD | -557.463% |
| Revelation Biosciences, Inc. | 5.56 Million USD | -13275.637% |
| Rigel Pharmaceuticals, Inc. | 145.86 Million USD | -410.28% |
| TransCode Therapeutics, Inc. | 3.52 Million USD | -20992.769% |
| Revolution Medicines, Inc. Warrant | 262.39 Million USD | -183.669% |
| Reviva Pharmaceuticals Holdings, Inc. | 6.6 Million USD | -11165.454% |
| Sesen Bio, Inc. | 30.98 Million USD | -2302.337% |
| Sangamo Therapeutics, Inc. | 82.43 Million USD | -802.964% |
| Solid Biosciences Inc. | 38.45 Million USD | -1835.462% |
| Syndax Pharmaceuticals, Inc. | 58.68 Million USD | -1168.387% |
| SciSparc Ltd. | 1.59 Million USD | -46567.085% |
| Sutro Biopharma, Inc. | 321.08 Million USD | -131.819% |
| TG Therapeutics, Inc. | 169.08 Million USD | -340.216% |
| Tonix Pharmaceuticals Holding Corp. | 48.93 Million USD | -1421.172% |
| Titan Pharmaceuticals, Inc. | 1.44 Million USD | -51447.091% |
| Travere Therapeutics, Inc. | 588.1 Million USD | -26.566% |
| UroGen Pharma Ltd. | 243.52 Million USD | -205.655% |
| Verrica Pharmaceuticals Inc. | 61.83 Million USD | -1103.771% |
| XOMA Corporation | 145.58 Million USD | -411.293% |
| Zentalis Pharmaceuticals, Inc. | 124.63 Million USD | -497.211% |
| AbCellera Biologics Inc. | 335.77 Million USD | -121.678% |
| Longboard Pharmaceuticals, Inc. | 9.77 Million USD | -7515.511% |
| Cassava Sciences, Inc. | 14.19 Million USD | -5143.677% |
| Corbus Pharmaceuticals Holdings, Inc. | 35.17 Million USD | -2015.978% |
| Precision BioSciences, Inc. | 140.92 Million USD | -428.2% |
| Dyadic International, Inc. | 2.34 Million USD | -31700.555% |
| Intensity Therapeutics, Inc. | 4.13 Million USD | -17909.678% |
| Eton Pharmaceuticals, Inc. | 16.26 Million USD | -4476.892% |
| VYNE Therapeutics Inc. | 8.95 Million USD | -8216.648% |
| Tenaya Therapeutics, Inc. | 31.09 Million USD | -2294.069% |
| IGM Biosciences, Inc. | 220.17 Million USD | -238.064% |
| X4 Pharmaceuticals, Inc. | 96.15 Million USD | -674.072% |
| Acelyrin, Inc. | 86.35 Million USD | -761.974% |
| Abeona Therapeutics Inc. | 49.17 Million USD | -1413.625% |
| Ligand Pharmaceuticals Incorporated | 130.7 Million USD | -469.472% |
| Inhibikase Therapeutics, Inc. | 3.52 Million USD | -20993.738% |
| Arcturus Therapeutics Holdings Inc. | 150.88 Million USD | -393.303% |
| Syros Pharmaceuticals, Inc. | 151.51 Million USD | -391.275% |
| Senti Biosciences, Inc. | 52.57 Million USD | -1315.876% |
| Mesoblast Limited | 188.79 Million USD | -294.252% |
| Kymera Therapeutics, Inc. | 180.78 Million USD | -311.72% |
| ChromaDex Corporation | 26.5 Million USD | -2707.982% |
| BriaCell Therapeutics Corp. | 8.55 Million USD | -8598.413% |
| Akebia Therapeutics, Inc. | 272.28 Million USD | -173.366% |
| Dermata Therapeutics, Inc. | 1.62 Million USD | -45744.584% |
| Seer, Inc. | 39.36 Million USD | -1790.868% |
| Xeris Biopharma Holdings, Inc. | 347.58 Million USD | -114.149% |
| Novavax, Inc. | 2.57 Billion USD | 71.063% |
| Virpax Pharmaceuticals, Inc. | 7.69 Million USD | -9574.261% |
| Fate Therapeutics, Inc. | 137.8 Million USD | -440.16% |
| Checkpoint Therapeutics, Inc. | 18.42 Million USD | -3939.837% |
| Lyell Immunopharma, Inc. | 95.07 Million USD | -682.881% |
| Celcuity Inc. | 51.45 Million USD | -1346.723% |
| ContextLogic Inc. | 206 Million USD | -261.33% |
| Phathom Pharmaceuticals, Inc. | 486.6 Million USD | -52.967% |
| HOOKIPA Pharma Inc. | 71.48 Million USD | -941.326% |
| Jazz Pharmaceuticals plc | 7.65 Billion USD | 90.278% |
| Amarin Corporation plc | 279.58 Million USD | -166.228% |
| AnaptysBio, Inc. | 364.28 Million USD | -104.328% |
| Aptevo Therapeutics Inc. | 12.62 Million USD | -5797.631% |
| Aptorum Group Limited | 5.25 Million USD | -14059.732% |
| Cartesian Therapeutics, Inc. | 745.23 Million USD | 0.12% |
| Arrowhead Pharmaceuticals, Inc. | 478.39 Million USD | -55.593% |
| Ardelyx, Inc. | 130.76 Million USD | -469.228% |
| Celularity Inc. | 102.92 Million USD | -623.159% |
| Omeros Corporation | 403.25 Million USD | -84.584% |
| Humacyte, Inc. | 114.67 Million USD | -549.075% |
| Immunocore Holdings plc | 228.15 Million USD | -226.239% |
| IO Biotech, Inc. | 17.55 Million USD | -4139.804% |
| GT Biopharma, Inc. | 6.63 Million USD | -11121.77% |
| Cabaletta Bio, Inc. | 17.45 Million USD | -4165.07% |
| Summit Therapeutics Inc. | 125.25 Million USD | -494.25% |
| Alaunos Therapeutics, Inc. | 1.95 Million USD | -37954.192% |
| Pulmatrix, Inc. | 15.96 Million USD | -4562.908% |
| Intellia Therapeutics, Inc. | 250.8 Million USD | -196.777% |
| Evogene Ltd. | 17.99 Million USD | -4037.521% |
| CorMedix Inc. | 11.91 Million USD | -6145.758% |
| BioLineRx Ltd. | 50.7 Million USD | -1368.068% |
| VistaGen Therapeutics, Inc. | 9.36 Million USD | -7846.408% |
| Sagimet Biosciences Inc. | 5.65 Million USD | -13064.839% |
| PTC Therapeutics, Inc. | 2.72 Billion USD | 72.652% |
| scPharmaceuticals Inc. | 57.26 Million USD | -1199.907% |
| Fulcrum Therapeutics, Inc. | 22.5 Million USD | -3208.031% |
| Corcept Therapeutics Incorporated | 114.81 Million USD | -548.312% |
| NLS Pharmaceutics AG | 10.68 Million USD | -6869.343% |
| Reviva Pharmaceuticals Holdings, Inc. | 6.6 Million USD | -11165.454% |
| Akero Therapeutics, Inc. | 44.96 Million USD | -1555.376% |
| Eliem Therapeutics, Inc. | 2.87 Million USD | -25835.192% |
| Lisata Therapeutics, Inc. | 6.8 Million USD | -10846.176% |
| Stoke Therapeutics, Inc. | 68.77 Million USD | -982.251% |
| Reneo Pharmaceuticals, Inc. | 18.82 Million USD | -3853.787% |
| Outlook Therapeutics, Inc. | 46.73 Million USD | -1492.546% |
| ProMIS Neurosciences, Inc. | 12.38 Million USD | -5908.546% |
| Daré Bioscience, Inc. | 26.32 Million USD | -2726.981% |
| bluebird bio, Inc. | 424.62 Million USD | -75.294% |
| BioMarin Pharmaceutical Inc. | 1.89 Billion USD | 60.618% |
| DBV Technologies S.A. | 42.8 Million USD | -1639.112% |
| Avidity Biosciences, Inc. | 127.79 Million USD | -482.467% |
| Galecto, Inc. | 5.89 Million USD | -12524.491% |
| Sensei Biotherapeutics, Inc. | 9.47 Million USD | -7752.516% |
| Spruce Biosciences, Inc. | 27.43 Million USD | -2612.906% |
| Inhibrx Biosciences, Inc. | 264.39 Million USD | -181.531% |
| GlycoMimetics, Inc. | 6.9 Million USD | -10684.295% |
| Arcutis Biotherapeutics, Inc. | 252.69 Million USD | -194.557% |
| ADMA Biologics, Inc. | 193.97 Million USD | -283.728% |
| Clene Inc. | 38.95 Million USD | -1810.965% |
| Recursion Pharmaceuticals, Inc. | 190.26 Million USD | -291.216% |
| Aptose Biosciences Inc. | 15.8 Million USD | -4608.42% |
| ZyVersa Therapeutics, Inc. | 11.03 Million USD | -6642.402% |
| Soligenix, Inc. | 7.27 Million USD | -10131.613% |
| Century Therapeutics, Inc. | 175.94 Million USD | -323.062% |
| Kura Oncology, Inc. | 51.66 Million USD | -1340.788% |
| Surrozen, Inc. | 8.14 Million USD | -9038.613% |
| TScan Therapeutics, Inc. | 121.28 Million USD | -513.727% |
| Ocean Biomedical, Inc. | 6.61 Million USD | -11154.253% |
| CytomX Therapeutics, Inc. | 252.59 Million USD | -194.674% |
| Autolus Therapeutics plc | 263.9 Million USD | -182.046% |
| Mineralys Therapeutics, Inc. | 10.48 Million USD | -7001.126% |
| Eterna Therapeutics Inc. | 46.89 Million USD | -1487.113% |
| Caribou Biosciences, Inc. | 72.56 Million USD | -925.728% |
| GRI Bio, Inc. | 2.69 Million USD | -27498.813% |
| Xenetic Biosciences, Inc. | 809.58 Thousand USD | -91840.933% |
| Janux Therapeutics, Inc. | 36.05 Million USD | -1964.285% |
| INmune Bio, Inc. | 18.86 Million USD | -3846.241% |
| Heron Therapeutics, Inc. | 256.47 Million USD | -190.215% |
| SAB Biotherapeutics, Inc. | 26.64 Million USD | -2693.879% |
| Pasithea Therapeutics Corp. | 2.71 Million USD | -27281.488% |
| Tenax Therapeutics, Inc. | 3.58 Million USD | -20653.823% |
| Jaguar Health, Inc. | 45.86 Million USD | -1522.858% |
| Entero Therapeutics, Inc. | 3.28 Million USD | -22591.452% |
| Milestone Pharmaceuticals Inc. | 58.45 Million USD | -1173.356% |
| Clearside Biomedical, Inc. | 49.93 Million USD | -1390.767% |
| Atara Biotherapeutics, Inc. | 264.73 Million USD | -181.164% |
| Coherus BioSciences, Inc. | 823.02 Million USD | 9.561% |
| Verastem, Inc. | 71.18 Million USD | -945.642% |
| Pliant Therapeutics, Inc. | 38.57 Million USD | -1829.442% |
| Histogen Inc. | 5.69 Million USD | -12965.473% |
| Aprea Therapeutics, Inc. | 4.38 Million USD | -16872.345% |
| ACADIA Pharmaceuticals Inc. | 317.2 Million USD | -134.659% |
| Surrozen, Inc. | 8.14 Million USD | -9038.613% |
| Organovo Holdings, Inc. | 2.74 Million USD | -26986.608% |
| Lixte Biotechnology Holdings, Inc. | 313.85 Thousand USD | -237058.205% |
| Cadrenal Therapeutics, Inc. Common Stock | 826.87 Thousand USD | -89918.443% |
| Centessa Pharmaceuticals plc | 126.72 Million USD | -487.366% |
| Hepion Pharmaceuticals, Inc. | 10.81 Million USD | -6783.375% |
| BioRestorative Therapies, Inc. | 2.6 Million USD | -28447.814% |
| Kronos Bio, Inc. | 54.2 Million USD | -1273.296% |
| Turnstone Biologics Corp. | 14.14 Million USD | -5161.097% |
| Synaptogenix, Inc. | 5.52 Million USD | -13361.329% |
| Tiziana Life Sciences Ltd | 6.64 Million USD | -11096.45% |
| Entrada Therapeutics, Inc. | 226.83 Million USD | -228.146% |
| Aurinia Pharmaceuticals Inc. | 170.1 Million USD | -337.569% |
| Exelixis, Inc. | 678.44 Million USD | -9.713% |
| Nurix Therapeutics, Inc. | 164.04 Million USD | -353.739% |
| Apellis Pharmaceuticals, Inc. | 594.2 Million USD | -25.266% |
| Jasper Therapeutics, Inc. | 14.67 Million USD | -4971.818% |
| ESSA Pharma Inc. | 3.49 Million USD | -21196.849% |
| TNF Pharmaceuticals, Inc. | 5.08 Million USD | -14527.521% |
| Avid Bioservices, Inc. | 275.66 Million USD | -170.013% |
| Insmed Incorporated | 1.66 Billion USD | 55.208% |
| MediWound Ltd. | 27.18 Million USD | -2637.853% |
| OmniAb, Inc. | 87.4 Million USD | -751.648% |
| Alector, Inc. | 487.66 Million USD | -52.632% |
| Seres Therapeutics, Inc. | 403.45 Million USD | -84.491% |
| Zai Lab Limited | 240.17 Million USD | -209.913% |
| AlloVir, Inc. | 45.01 Million USD | -1553.538% |
| Revance Therapeutics, Inc. | 630.05 Million USD | -18.138% |
| ORIC Pharmaceuticals, Inc. | 30.59 Million USD | -2332.643% |
| Aura Biosciences, Inc. | 29.22 Million USD | -2446.755% |
| Immunic, Inc. | 25.36 Million USD | -2834.169% |
| Tarsus Pharmaceuticals, Inc. | 69.23 Million USD | -975.077% |
| Veracyte, Inc. | 93.71 Million USD | -694.225% |
| InMed Pharmaceuticals Inc. | 2.61 Million USD | -28346.046% |
| FibroGen, Inc. | 585.72 Million USD | -27.079% |
| SeaStar Medical Holding Corporation | 17.38 Million USD | -4182.0% |
| Catalyst Pharmaceuticals, Inc. | 84.02 Million USD | -785.845% |
| Adial Pharmaceuticals, Inc. | 653.07 Thousand USD | -113874.484% |
| Sonnet BioTherapeutics Holdings, Inc. | 5.65 Million USD | -13061.445% |
| Cyclacel Pharmaceuticals, Inc. | 8.19 Million USD | -8979.532% |
| Amylyx Pharmaceuticals, Inc. | 84.02 Million USD | -785.887% |
| Fortrea Holdings Inc. | 2.61 Billion USD | 71.573% |
| KalVista Pharmaceuticals, Inc. | 28.82 Million USD | -2482.541% |
| XBiotech Inc. | 8.39 Million USD | -8764.356% |
| Jasper Therapeutics, Inc. | 14.67 Million USD | -4971.818% |
| Keros Therapeutics, Inc. | 37.81 Million USD | -1868.529% |
| SELLAS Life Sciences Group, Inc. | 14.37 Million USD | -5076.577% |
| Lyra Therapeutics, Inc. | 53.18 Million USD | -1299.662% |
| Foghorn Therapeutics Inc. | 363.1 Million USD | -104.992% |
| Agenus Inc. | 462.29 Million USD | -61.01% |
| Y-mAbs Therapeutics, Inc. | 26.88 Million USD | -2668.71% |
| Theravance Biopharma, Inc. | 169 Million USD | -340.427% |
| Ultragenyx Pharmaceutical Inc. | 1.21 Billion USD | 38.768% |
| Metagenomi, Inc. Common Stock | 500.42 Million USD | -48.741% |
| BioCryst Pharmaceuticals, Inc. | 972.48 Million USD | 23.46% |
| Gain Therapeutics, Inc. | 6.03 Million USD | -12241.681% |
| C4 Therapeutics, Inc. | 130.33 Million USD | -471.089% |
| Creative Medical Technology Holdings, Inc. | 371.39 Thousand USD | -200317.885% |
| Chemomab Therapeutics Ltd. | 5.15 Million USD | -14341.903% |
| Lantern Pharma Inc. | 2.73 Million USD | -27068.847% |
| Eledon Pharmaceuticals, Inc. | 42.47 Million USD | -1652.419% |
| Ainos, Inc. | 7.39 Million USD | -9966.507% |
| Pluri Inc. | 34.11 Million USD | -2082.047% |
| Prothena Corporation plc | 135.01 Million USD | -451.294% |
| Adaptimmune Therapeutics plc | 243.1 Million USD | -206.183% |
| Rallybio Corporation | 9.43 Million USD | -7788.3% |
| Kodiak Sciences Inc. | 213.59 Million USD | -248.488% |
| Cue Biopharma, Inc. | 24.44 Million USD | -2944.958% |
| MeiraGTx Holdings plc | 319.99 Million USD | -132.613% |
| Annexon, Inc. | 47.11 Million USD | -1479.736% |
| Assembly Biosciences, Inc. | 96.37 Million USD | -672.361% |
| Moderna, Inc. | 4.57 Billion USD | 83.72% |
| Cocrystal Pharma, Inc. | 4.87 Million USD | -15168.513% |
| Cidara Therapeutics, Inc. | 76.74 Million USD | -869.95% |
| Blueprint Medicines Corporation | 918.64 Million USD | 18.974% |
| Immix Biopharma, Inc. | 3.72 Million USD | -19899.554% |
| CalciMedica, Inc. | 4.02 Million USD | -18379.146% |
| Monte Rosa Therapeutics, Inc. | 124.5 Million USD | -497.839% |
| Scholar Rock Holding Corporation | 85.81 Million USD | -767.357% |
| Wave Life Sciences Ltd. | 227.44 Million USD | -227.262% |
| Sana Biotechnology, Inc. | 277.79 Million USD | -167.948% |
| Elicio Therapeutics, Inc. | 15.77 Million USD | -4619.077% |
| Adlai Nortye Ltd. American Depositary Shares | 50.78 Million USD | -1365.64% |
| Nutriband Inc. | 1.07 Million USD | -68889.424% |
| Protara Therapeutics, Inc. | 10.63 Million USD | -6900.282% |
| Vor Biopharma Inc. | 59.1 Million USD | -1159.373% |
| Roivant Sciences Ltd. | 773.95 Million USD | 3.826% |
| Alkermes plc | 933.53 Million USD | 20.267% |
| ProKidney Corp. | 29.21 Million USD | -2447.714% |
| Applied Therapeutics, Inc. | 71.97 Million USD | -934.107% |
| Arcellx, Inc. | 339.75 Million USD | -119.083% |
| BridgeBio Pharma, Inc. | 1.88 Billion USD | 60.594% |
| Tango Therapeutics, Inc. | 149.45 Million USD | -398.023% |
| Galectin Therapeutics Inc. | 88.44 Million USD | -741.623% |
| Atai Life Sciences N.V. | 49.16 Million USD | -1414.056% |
| Renovaro Biosciences Inc. | 31.15 Million USD | -2289.358% |
| Aerovate Therapeutics, Inc. | 17.96 Million USD | -4043.971% |
| MediciNova, Inc. | 3.89 Million USD | -19027.068% |
| Praxis Precision Medicines, Inc. | 18.27 Million USD | -3972.105% |
| Cardio Diagnostics Holdings, Inc. | 1.5 Million USD | -49382.762% |
| GeoVax Labs, Inc. | 3.51 Million USD | -21046.738% |
| Axsome Therapeutics, Inc. | 397.25 Million USD | -87.369% |
| Biomea Fusion, Inc. | 30.69 Million USD | -2325.35% |
| RenovoRx, Inc. | 4.46 Million USD | -16566.816% |
| Cullinan Oncology, Inc. | 31.2 Million USD | -2285.629% |
| Geron Corporation | 146.12 Million USD | -409.379% |
| NRx Pharmaceuticals, Inc. | 19.04 Million USD | -3807.707% |
| 4D Molecular Therapeutics, Inc. | 32.06 Million USD | -2221.565% |
| Dyne Therapeutics, Inc. | 73.79 Million USD | -908.727% |
| Kiniksa Pharmaceuticals, Ltd. | 87.48 Million USD | -750.84% |
| Royalty Pharma plc | 6.29 Billion USD | 88.181% |
| Ventyx Biosciences, Inc. | 33.77 Million USD | -2104.146% |
| Imunon, Inc. | 8.53 Million USD | -8625.706% |
| BioAtla, Inc. | 48.98 Million USD | -1419.495% |
| Allogene Therapeutics, Inc. | 130.6 Million USD | -469.921% |
| Larimar Therapeutics, Inc. | 14.21 Million USD | -5136.3% |
| Mersana Therapeutics, Inc. | 189.15 Million USD | -293.506% |
| Structure Therapeutics Inc. | 29.05 Million USD | -2462.183% |
| 89bio, Inc. | 59.96 Million USD | -1141.332% |
| Kezar Life Sciences, Inc. | 33.66 Million USD | -2111.02% |
| aTyr Pharma, Inc. | 31.59 Million USD | -2255.73% |
| Aligos Therapeutics, Inc. | 61.82 Million USD | -1103.986% |
| Viridian Therapeutics, Inc. | 48.4 Million USD | -1437.829% |
| EyeGate Pharmaceuticals, Inc. | 8.15 Million USD | -9024.03% |
| Akari Therapeutics, Plc | 4.58 Million USD | -16137.784% |
| Tevogen Bio Holdings Inc. | 17.73 Million USD | -4097.454% |
| Halozyme Therapeutics, Inc. | 1.64 Billion USD | 54.874% |
| Lexicon Pharmaceuticals, Inc. | 136.31 Million USD | -446.028% |
| Liquidia Corporation | 73.13 Million USD | -917.72% |
| Entera Bio Ltd. | 1.37 Million USD | -53876.795% |
| GH Research PLC | 6.7 Million USD | -11007.894% |
| Vericel Corporation | 127.7 Million USD | -482.859% |
| Arbutus Biopharma Corporation | 38.38 Million USD | -1839.244% |
| Xencor, Inc. | 283.55 Million USD | -162.499% |
| 60 Degrees Pharmaceuticals, Inc. | 2.98 Million USD | -24830.376% |
| Pasithea Therapeutics Corp. | 2.71 Million USD | -27281.488% |
| Coeptis Therapeutics Holdings, Inc. | 3.75 Million USD | -19711.425% |
| Vaxcyte, Inc. | 167.44 Million USD | -344.517% |
| Xenon Pharmaceuticals Inc. | 36.87 Million USD | -1918.44% |
| Vanda Pharmaceuticals Inc. | 103.53 Million USD | -618.961% |
| Lexaria Bioscience Corp. | 403.9 Thousand USD | -184184.54% |
| Portage Biotech Inc. | 4.45 Million USD | -16626.742% |
| Cardio Diagnostics Holdings, Inc. | 1.5 Million USD | -49382.762% |
| Olema Pharmaceuticals, Inc. | 23.05 Million USD | -3129.241% |
| OncoCyte Corporation | 49.29 Million USD | -1409.879% |
| Qualigen Therapeutics, Inc. | 4.13 Million USD | -17893.113% |
| Processa Pharmaceuticals, Inc. | 797.48 Thousand USD | -93236.042% |
| Purple Biotech Ltd. | 10 Million USD | -7339.68% |
| Tempest Therapeutics, Inc. | 24.83 Million USD | -2897.141% |
| Sol-Gel Technologies Ltd. | 6.64 Million USD | -11104.877% |
| Rhythm Pharmaceuticals, Inc. | 162.98 Million USD | -356.69% |
| CollPlant Biotechnologies Ltd. | 5.78 Million USD | -12764.501% |
| Moleculin Biotech, Inc. | 12.14 Million USD | -6029.282% |
| United Therapeutics Corporation | 1.18 Billion USD | 37.038% |
| HilleVax, Inc. | 78.9 Million USD | -843.289% |
| Silo Pharma, Inc. | 1.56 Million USD | -47332.246% |
| Telomir Pharmaceuticals, Inc. Common Stock | 1.33 Million USD | -55632.26% |
| Pharming Group N.V. | 244.07 Million USD | -204.966% |
| Tharimmune, Inc. | 1.81 Million USD | -40909.429% |
| Genprex, Inc. | 3.25 Million USD | -22773.154% |
| Apogee Therapeutics, Inc. | 21.49 Million USD | -3363.496% |
| Neumora Therapeutics, Inc. Common Stock | 27.11 Million USD | -2644.718% |
| Pyxis Oncology, Inc. | 48.02 Million USD | -1449.998% |
| XTL Biopharmaceuticals Ltd. | 206 Thousand USD | -361230.097% |
| Virios Therapeutics, Inc. | 358.54 Thousand USD | -207498.425% |
| OKYO Pharma Limited | 7.42 Million USD | -9930.393% |
| Savara Inc. | 37.19 Million USD | -1901.344% |
| Windtree Therapeutics, Inc. | 29.01 Million USD | -2465.363% |
| Curis, Inc. | 57.61 Million USD | -1191.988% |
| Carmell Therapeutics Corporation | 39.19 Million USD | -1798.837% |
| Achieve Life Sciences, Inc. | 20.81 Million USD | -3475.292% |
| BeiGene, Ltd. | 2.23 Billion USD | 66.677% |
| Protagonist Therapeutics, Inc. | 21.27 Million USD | -3398.825% |
| Erasca, Inc. | 78.61 Million USD | -846.865% |
| Protagenic Therapeutics, Inc. | 655.25 Thousand USD | -113495.991% |
| Protagenic Therapeutics, Inc. | 655.25 Thousand USD | -113495.991% |
| Vincerx Pharma, Inc. | 6.99 Million USD | -10541.029% |
| Fresh Tracks Therapeutics, Inc. | 1.65 Million USD | -44848.068% |
| Acrivon Therapeutics, Inc. Common Stock | 17.07 Million USD | -4260.516% |
| Celldex Therapeutics, Inc. | 36.45 Million USD | -1941.749% |
| Cogent Biosciences, Inc. | 55.63 Million USD | -1237.899% |
| Adicet Bio, Inc. | 37.12 Million USD | -1905.226% |
| Amicus Therapeutics, Inc. | 617.7 Million USD | -20.501% |
| Aditxt, Inc. | 28.53 Million USD | -2508.831% |
| Adagene Inc. | 45.16 Million USD | -1547.888% |
| Estrella Immunopharma, Inc. | 180.7 Thousand USD | -411818.03% |
| Quantum-Si incorporated | 26.63 Million USD | -2695.013% |
| Acurx Pharmaceuticals, Inc. | 3.04 Million USD | -24365.248% |
| Voyager Therapeutics, Inc. | 114.96 Million USD | -547.472% |
| Compugen Ltd. | 55.77 Million USD | -1234.541% |
| Generation Bio Co. | 171.63 Million USD | -333.689% |
| Astria Therapeutics, Inc. | 11.55 Million USD | -6344.502% |
| Black Diamond Therapeutics, Inc. | 41.83 Million USD | -1679.398% |
| Invivyd, Inc. | 51.71 Million USD | -1339.367% |
| Relay Therapeutics, Inc. | 91.97 Million USD | -709.268% |
| Quoin Pharmaceuticals, Ltd. | 6.5 Million USD | -11342.141% |
| Spero Therapeutics, Inc. | 75.49 Million USD | -885.933% |
| Artelo Biosciences, Inc. | 1.02 Million USD | -72803.036% |
| 2seventy bio, Inc. | 310.12 Million USD | -140.012% |
| Instil Bio, Inc. | 99.8 Million USD | -645.824% |
| Capricor Therapeutics, Inc. | 36.13 Million USD | -1960.009% |
| Elevai Labs, Inc. Common Stock | 1.36 Million USD | -54516.749% |
| GeoVax Labs, Inc. | 3.51 Million USD | -21046.738% |
| Citius Pharmaceuticals, Inc. | 12.17 Million USD | -6011.335% |
| Relmada Therapeutics, Inc. | 12.19 Million USD | -6003.749% |
| ALX Oncology Holdings Inc. | 52.84 Million USD | -1308.641% |
| Vir Biotechnology, Inc. | 369.85 Million USD | -101.252% |
| Evaxion Biotech A/S | 17.61 Million USD | -4125.008% |
| Ocular Therapeutix, Inc. | 160.92 Million USD | -362.527% |
| Verve Therapeutics, Inc. | 153.18 Million USD | -385.906% |
| Tyra Biosciences, Inc. | 21.59 Million USD | -3346.816% |
| Cingulate Inc. | 10.36 Million USD | -7084.149% |
| Galmed Pharmaceuticals Ltd. | 2.75 Million USD | -26966.909% |
| Unity Biotechnology, Inc. | 37.29 Million USD | -1895.978% |
| Connect Biopharma Holdings Limited | 24.84 Million USD | -2895.453% |
| Clearmind Medicine Inc. | 3.61 Million USD | -20518.791% |
| Bolt Biotherapeutics, Inc. | 47.04 Million USD | -1482.255% |
| CERo Therapeutics Holdings, Inc. | 22.75 Million USD | -3170.425% |
| Viking Therapeutics, Inc. | 20.07 Million USD | -3608.535% |
| Madrigal Pharmaceuticals, Inc. | 235.21 Million USD | -216.452% |
| ImmunityBio, Inc. | 1.09 Billion USD | 31.736% |
| Korro Bio, Inc. | 51.75 Million USD | -1338.283% |
| Kineta, Inc. | 7.22 Million USD | -10206.563% |
| BioVie Inc. | 9.7 Million USD | -7571.924% |
| Codexis, Inc. | 49.94 Million USD | -1390.29% |
| Celularity Inc. | 102.92 Million USD | -623.159% |
| Aileron Therapeutics, Inc. | 112.39 Million USD | -562.23% |
| Crinetics Pharmaceuticals, Inc. | 96.24 Million USD | -673.364% |
| Virax Biolabs Group Limited | 345.19 Thousand USD | -215529.472% |
| Cibus, Inc. | 206.11 Million USD | -261.125% |
| IN8bio, Inc. | 8.77 Million USD | -8385.408% |
| Adverum Biotechnologies, Inc. | 89.54 Million USD | -731.284% |
| Avalo Therapeutics, Inc. | 13.68 Million USD | -5337.505% |
| Ionis Pharmaceuticals, Inc. | 2.6 Billion USD | 71.409% |
| Eyenovia, Inc. | 19.78 Million USD | -3663.041% |
| Puma Biotechnology, Inc. | 177.08 Million USD | -320.327% |
| Conduit Pharmaceuticals Inc. | 7.68 Million USD | -9590.665% |
| Elevation Oncology, Inc. | 34.28 Million USD | -2071.227% |
| Xilio Therapeutics, Inc. | 24.09 Million USD | -2988.676% |
| Cardiff Oncology, Inc. | 11.89 Million USD | -6156.009% |
| Enanta Pharmaceuticals, Inc. | 245.54 Million USD | -203.144% |
| Regulus Therapeutics Inc. | 9.56 Million USD | -7683.541% |
| Moolec Science SA | 13.94 Million USD | -5237.547% |
| Acumen Pharmaceuticals, Inc. | 43.15 Million USD | -1624.926% |
| LAVA Therapeutics N.V. | 50.53 Million USD | -1373.007% |
| Atea Pharmaceuticals, Inc. | 39.77 Million USD | -1771.329% |
| Compass Therapeutics, Inc. | 8.33 Million USD | -8828.152% |
| Greenwich LifeSciences, Inc. | 294.4 Thousand USD | -252727.728% |
| TFF Pharmaceuticals, Inc. | 2.46 Million USD | -30154.255% |
| Humacyte, Inc. | 114.67 Million USD | -549.075% |
| PMV Pharmaceuticals, Inc. | 26.46 Million USD | -2712.757% |
| Avenue Therapeutics, Inc. | 1.19 Million USD | -62135.786% |
| Genelux Corporation | 8.42 Million USD | -8740.143% |
| Trevi Therapeutics, Inc. | 6.85 Million USD | -10756.768% |
| Notable Labs, Ltd. | 4.42 Million USD | -16713.644% |
| Immunovant, Inc. | 48.95 Million USD | -1420.458% |
| Quantum-Si incorporated | 26.63 Million USD | -2695.013% |
| DiaMedica Therapeutics Inc. | 3.1 Million USD | -23887.754% |
| Vera Therapeutics, Inc. | 73.86 Million USD | -907.758% |
| Acasti Pharma Inc. | 11.55 Million USD | -6340.599% |
| MiNK Therapeutics, Inc. | 22.6 Million USD | -3192.414% |
| Soleno Therapeutics, Inc. | 23.18 Million USD | -3110.576% |
| PepGen Inc. | 34.63 Million USD | -2049.346% |
| Nuvectis Pharma, Inc. | 6.98 Million USD | -10557.789% |
| BriaCell Therapeutics Corp. | 8.55 Million USD | -8598.413% |
| Immuneering Corporation | 12 Million USD | -6098.518% |
| Lixte Biotechnology Holdings, Inc. | 313.85 Thousand USD | -237058.205% |
| Belite Bio, Inc | 4.21 Million USD | -17576.086% |
| XOMA Corporation | 145.58 Million USD | -411.293% |
| ARS Pharmaceuticals, Inc. | 2.42 Million USD | -30556.507% |
| Bionomics Limited | 10.15 Million USD | -7227.103% |
| Alpha Tau Medical Ltd. | 22.91 Million USD | -3148.549% |
| uniQure N.V. | 624.01 Million USD | -19.282% |
| Estrella Immunopharma, Inc. | 180.7 Thousand USD | -411818.03% |
| Poseida Therapeutics, Inc. | 170.18 Million USD | -337.374% |
| Forte Biosciences, Inc. | 3.66 Million USD | -20203.873% |
| Anebulo Pharmaceuticals, Inc. | 260.58 Thousand USD | -285544.113% |
| Enlivex Therapeutics Ltd. | 6.74 Million USD | -10932.162% |
| Conduit Pharmaceuticals Inc. | 7.68 Million USD | -9590.665% |
| SeaStar Medical Holding Corporation | 17.38 Million USD | -4182.0% |
| FibroBiologics, Inc. Common Stock | 10.56 Million USD | -6943.338% |
| Altimmune, Inc. | 16.54 Million USD | -4399.97% |
| LENZ Therapeutics, Inc. | 4.87 Million USD | -15171.645% |
| Alpha Tau Medical Ltd. | 22.91 Million USD | -3148.549% |
| Peak Bio, Inc. | 20.75 Million USD | -3486.599% |
| Zevra Therapeutics, Inc. | 110.46 Million USD | -573.836% |
| Benitec Biopharma Inc. | 4.96 Million USD | -14900.806% |
| Spyre Therapeutics, Inc. | 157.84 Million USD | -371.57% |
| NKGen Biotech, Inc. Common Stock | 75.17 Million USD | -890.156% |
| Zura Bio Limited | 21.29 Million USD | -3395.867% |
| PolyPid Ltd. | 17.46 Million USD | -4161.163% |
| NKGen Biotech, Inc. Warrants | 75.17 Million USD | -890.156% |
| argenx SE | 444.95 Million USD | -67.286% |
| Immunome, Inc. | 28.65 Million USD | -2497.32% |
| Verona Pharma plc | 58.84 Million USD | -1165.002% |
| enGene Holdings Inc. Warrants | 14.47 Million USD | -5042.956% |
| Shattuck Labs, Inc. | 14.85 Million USD | -4909.355% |
| CervoMed Inc. | 2.59 Million USD | -28575.368% |
| Plus Therapeutics, Inc. | 12.73 Million USD | -5744.378% |
| Dianthus Therapeutics, Inc. | 10.53 Million USD | -6965.401% |
| Moolec Science SA | 13.94 Million USD | -5237.547% |
| Enveric Biosciences, Inc. | 2.34 Million USD | -31661.84% |
| Design Therapeutics, Inc. | 11.95 Million USD | -6125.661% |
| Leap Therapeutics, Inc. | 12.68 Million USD | -5768.338% |
| Seelos Therapeutics, Inc. | 38.92 Million USD | -1812.094% |
| Achilles Therapeutics plc | 19.08 Million USD | -3799.722% |
| CERo Therapeutics Holdings, Inc. | 22.75 Million USD | -3170.425% |
| CG Oncology, Inc. Common stock | 14.51 Million USD | -5029.488% |
| Fractyl Health, Inc. Common Stock | 401.27 Million USD | -85.494% |
| Rani Therapeutics Holdings, Inc. | 32.47 Million USD | -2192.181% |
| MoonLake Immunotherapeutics | 13.04 Million USD | -5604.15% |
| Tourmaline Bio, Inc. | 5.25 Million USD | -14069.808% |
| Beam Therapeutics Inc. | 478.38 Million USD | -55.594% |
| Mirum Pharmaceuticals, Inc. | 397.95 Million USD | -87.043% |
| AEON Biopharma, Inc. | 159.88 Million USD | -365.535% |
| Aadi Bioscience, Inc. | 27.22 Million USD | -2633.73% |
| Enliven Therapeutics, Inc. | 25.96 Million USD | -2767.147% |
| Kiora Pharmaceuticals, Inc. | 7.6 Million USD | -9691.092% |
| NeurAxis, Inc. | 1.91 Million USD | -38814.875% |
| Iovance Biotherapeutics, Inc. | 195.73 Million USD | -280.274% |
| Lumos Pharma, Inc. | 13.33 Million USD | -5482.69% |
| Opiant Pharmaceuticals, Inc. | 23.58 Million USD | -3055.589% |
| Palisade Bio, Inc. | 2.73 Million USD | -27075.612% |
| Nutriband Inc. | 1.07 Million USD | -68889.424% |
| Taysha Gene Therapies, Inc. | 192.05 Million USD | -287.562% |
| Neurogene Inc. | 36.54 Million USD | -1936.554% |
| Kintara Therapeutics, Inc. | 2.44 Million USD | -30343.354% |
| CARGO Therapeutics, Inc. Common Stock | 47.65 Million USD | -1462.099% |
| Athira Pharma, Inc. | 30.05 Million USD | -2376.428% |
| HCW Biologics Inc. | 15.05 Million USD | -4845.142% |
| XOMA Corporation | 145.58 Million USD | -411.293% |
| Nektar Therapeutics | 267.04 Million USD | -178.731% |
| Arvinas, Inc. | 644.6 Million USD | -15.473% |
| Tevogen Bio Holdings Inc. | 17.73 Million USD | -4097.454% |
| Merus N.V. | 102.15 Million USD | -628.666% |
| Omega Therapeutics, Inc. | 146.35 Million USD | -408.603% |
| Quince Therapeutics, Inc. | 95.12 Million USD | -682.527% |
| Rezolute, Inc. | 11.73 Million USD | -6243.446% |
| Clene Inc. | 38.95 Million USD | -1810.965% |
| Indaptus Therapeutics, Inc. | 2.84 Million USD | -26041.225% |
| BeyondSpring Inc. | 48.26 Million USD | -1442.066% |
| Synlogic, Inc. | 32.89 Million USD | -2162.775% |
| Allarity Therapeutics, Inc. | 14.61 Million USD | -4993.684% |
| Phio Pharmaceuticals Corp. | 1.63 Million USD | -45453.244% |
| Peak Bio, Inc. | 20.75 Million USD | -3486.599% |
| Werewolf Therapeutics, Inc. | 63.45 Million USD | -1072.946% |
| Krystal Biotech, Inc. | 39.71 Million USD | -1774.251% |
| Karyopharm Therapeutics Inc. | 376.64 Million USD | -97.624% |
| SpringWorks Therapeutics, Inc. | 99.56 Million USD | -647.562% |
| Lipella Pharmaceuticals Inc. | 432.72 Thousand USD | -171911.85% |
| MannKind Corporation | 721.36 Million USD | -3.185% |
| Ikena Oncology, Inc. | 22.33 Million USD | -3232.617% |
| Cyclerion Therapeutics, Inc. | 2.08 Million USD | -35582.646% |
| Gyre Therapeutics, Inc. | 102.59 Million USD | -625.548% |
| Gossamer Bio, Inc. | 249.14 Million USD | -198.755% |
| CohBar, Inc. | 1.03 Million USD | -71911.671% |
| Cognition Therapeutics, Inc. | 10.68 Million USD | -6863.607% |
| NRx Pharmaceuticals, Inc. | 19.04 Million USD | -3807.707% |
| Legend Biotech Corporation | 589.93 Million USD | -26.174% |
| Mural Oncology plc | 37.92 Million USD | -1862.508% |
| Disc Medicine, Inc. | 22.87 Million USD | -3153.945% |
| Champions Oncology, Inc. | 28.03 Million USD | -2555.038% |
| REGENXBIO Inc. | 262.22 Million USD | -183.852% |
| Ensysce Biosciences, Inc. | 3.35 Million USD | -22057.249% |
| Anavex Life Sciences Corp. | 12.53 Million USD | -5838.567% |
| Cellectar Biosciences, Inc. | 13.43 Million USD | -5441.696% |
| Edgewise Therapeutics, Inc. | 21.2 Million USD | -3410.21% |
| Vaxart, Inc. | 34.02 Million USD | -2087.627% |
| PharmaCyte Biotech, Inc. | 20.38 Million USD | -3550.647% |
| Aldeyra Therapeutics, Inc. | 28.53 Million USD | -2508.801% |
| Cellectis S.A. | 249.57 Million USD | -198.243% |
| Longeveron Inc. | 5.33 Million USD | -13846.787% |
| Repare Therapeutics Inc. | 41.81 Million USD | -1679.909% |
| Sarepta Therapeutics, Inc. | 2.4 Billion USD | 69.053% |
| Inozyme Pharma, Inc. | 60.36 Million USD | -1133.004% |
| Revolution Medicines, Inc. | 262.39 Million USD | -183.669% |
| Nymox Pharmaceutical Corporation | 2.1 Million USD | -35227.005% |
| Third Harmonic Bio, Inc. | 8.62 Million USD | -8529.029% |
| ArriVent BioPharma, Inc. Common Stock | 11.8 Million USD | -6207.432% |
| AN2 Therapeutics, Inc. | 14.04 Million USD | -5200.434% |
| Anixa Biosciences, Inc. | 2.15 Million USD | -34504.37% |
| Vertex Pharmaceuticals Incorporated | 5.14 Billion USD | 85.546% |
| Denali Therapeutics Inc. | 122.96 Million USD | -505.337% |
| Revelation Biosciences, Inc. | 5.56 Million USD | -13275.637% |
| Veru Inc. | 32.81 Million USD | -2168.451% |
| Corvus Pharmaceuticals, Inc. | 6.86 Million USD | -10736.221% |
| Cingulate Inc. | 10.36 Million USD | -7084.149% |
| Passage Bio, Inc. | 39.26 Million USD | -1795.828% |
| Context Therapeutics Inc. | 4.19 Million USD | -17657.41% |
| Exicure, Inc. | 8.54 Million USD | -8606.749% |
| Day One Biopharmaceuticals, Inc. | 29.5 Million USD | -2422.502% |
| Oramed Pharmaceuticals Inc. | 10.48 Million USD | -6998.417% |
| Scinai Immunotherapeutics Ltd. | 22.04 Million USD | -3277.07% |
| Nuvalent, Inc. | 31.82 Million USD | -2239.0% |
| ABVC BioPharma, Inc. | 6.36 Million USD | -11600.466% |
| Carisma Therapeutics, Inc. | 63.02 Million USD | -1081.08% |
| Unicycive Therapeutics, Inc. | 18 Million USD | -4035.222% |
| OmniAb, Inc. | 87.4 Million USD | -751.648% |
| Anew Medical, Inc. | 8.24 Million USD | -8931.281% |
| Fennec Pharmaceuticals Inc. | 38.28 Million USD | -1844.0% |
| Lipocine Inc. | 2.63 Million USD | -28184.382% |
| Lexeo Therapeutics, Inc. Common Stock | 26.27 Million USD | -2733.206% |
| Nautilus Biotechnology, Inc. | 40.21 Million USD | -1751.039% |
| SAB Biotherapeutics, Inc. | 26.64 Million USD | -2693.879% |
| G1 Therapeutics, Inc. | 86.15 Million USD | -763.965% |
| Bellerophon Therapeutics, Inc. | 5.4 Million USD | -13681.522% |
| Sage Therapeutics, Inc. | 82.74 Million USD | -799.537% |
| Ocugen, Inc. | 23.98 Million USD | -3003.615% |
| Mind Medicine (MindMed) Inc. | 46.4 Million USD | -1503.939% |
| Q32 Bio Inc. | 233.12 Million USD | -219.284% |
| Brainstorm Cell Therapeutics Inc. | 9.06 Million USD | -8110.236% |
| Alumis Inc. Common Stock | 53.5 Million USD | -1291.238% |
| Equillium, Inc. | 27.95 Million USD | -2562.446% |
| Kyverna Therapeutics, Inc. | 206.59 Million USD | -260.295% |
| Coya Therapeutics, Inc. | 5.62 Million USD | -13128.795% |
| CNS Pharmaceuticals, Inc. | 6.13 Million USD | -12036.701% |
| Dominari Holdings Inc. | 4.63 Million USD | -15959.115% |
| Edesa Biotech, Inc. | 1.84 Million USD | -40317.303% |
| vTv Therapeutics Inc. | 29.56 Million USD | -2417.469% |
| Agios Pharmaceuticals, Inc. | 126.09 Million USD | -490.282% |
| Harmony Biosciences Holdings, Inc. | 344.45 Million USD | -116.091% |
| Prelude Therapeutics Incorporated | 40.57 Million USD | -1734.479% |
| Candel Therapeutics, Inc. | 28.95 Million USD | -2470.501% |
| iTeos Therapeutics, Inc. | 92.36 Million USD | -705.912% |
| Nkarta, Inc. | 105.6 Million USD | -604.867% |
| BioCardia, Inc. | 4.59 Million USD | -16116.558% |
| Iterum Therapeutics plc | 32.66 Million USD | -2178.917% |